Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.

Files in this item

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics